Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Relapsing-remitting multiple sclerosis (RRMS) management often involves combination therapies.
• Subcutaneous interferon (IFN) β-1a is a standard treatment for RRMS.

Purpose of the Study:

• To evaluate the efficacy and safety of adding minocycline to subcutaneous interferon (IFN) β-1a in RRMS patients.
• To assess the impact on relapse rates, new MRI lesions, and brain volume changes.

Main Methods:

• A double-blind, randomized, placebo-controlled, multicentre study.
• RRMS patients received minocycline or placebo added to subcutaneous IFN β-1a for 96 weeks.
• Primary endpoint: time to first qualifying relapse; secondary endpoints included relapse rate and MRI lesion analysis.

Main Results:

• No significant difference in time to first relapse between minocycline and placebo groups (HR 0.85, P=0.48).
• No statistically significant differences observed in other efficacy endpoints, despite numerical trends favoring minocycline.
• More adverse event-related discontinuations occurred in the minocycline group.

Conclusions:

• Minocycline augmentation did not provide statistically significant benefits for RRMS patients on subcutaneous IFN β-1a.
• The combination therapy did not demonstrate superior efficacy compared to placebo.
• Safety profile indicated potential for increased adverse events with minocycline.